Histologic progression in non-hodgkin's lymphoma

Journal Article · Mon Feb 01 00:00:00 EST 1982 · Blood; (United States)

OSTI ID:5636704

Hubbard, S M ^[1]; Chabner, B A; DeVita, Jr, V T; Simon, R; Berard, C W; Jones, R B; Garvin, A J; Canellos, G P; Osborne, C K; Young, R C

---

1. National Cancer Inst., Bethesda, MD

The clinical course and biopsy specimens from 515 consecutive non-Hodgkin's lymphoma patients was evaluated retrospectively in an attempt to determine the clinical importance of documented changes in histology over time. Two-hundred and five of these patients has an initial diagnosis of nodular lymphoma and were reviewed for this anaysis. Sixty-three underwent a repeat biopsy greater than 6 mo after initial diagnosis. In 23 patients, these repeat biopsies revealed a change in histology to a diffuse pattern and/or a change to a larger ''histiocytic'' cell type, while repeat biopsies for the other 40 (63%) disclosd persistence of a nodular pattern and no clear change in basic cell type. Progression from nodular lymphoma to diffuse histiocytic, mixed, or undifferentiated types of lymphomas of Rappaport was found in repeate biopsies obtained from 19 patients (30%). Prognosis for survival following a biopsy that demonstrated histologic change was related to the histology demonstrated at the most recent biopsy and to the response to subsequent drug treatment. Survival following repeat biopsy for these 19 patients was significantly shorter than for the 40 patients whose histology remained nodular (p < 0.001). However, attainment of a complete remission with intensive combination chemotherapy was associated with prolonged survival in eight patients and prolonged disease-free survival in one patient. Since prior treatment may compromise the ability to achieve a complete response to chemotherapy in patients with nodular lymphoma who develop an aggressive diffuse histology, the likelihood of histologic progression must be considered in the design of future clinical trials in nodular lymphoma. Histologic progression does not preclude attainment of a complete response to intensive chemotherapy.

• OSTI ID: 5636704
• Journal Information: Blood; (United States), Vol. 59:2
• Country of Publication: United States
• Language: English

Related Subjects

63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
LYMPHOMAS
BIOLOGICAL RADIATION EFFECTS
RADIOTHERAPY
SIDE EFFECTS
BIOPSY
CHEMOTHERAPY
HISTOLOGY
MUTAGENESIS
PATIENTS
SURVIVAL TIME
BIOLOGICAL EFFECTS
DIAGNOSTIC TECHNIQUES
DISEASES
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
RADIATION EFFECTS
RADIOLOGY
THERAPY
560151* - Radiation Effects on Animals- Man